HGH Fragment 176-191
Also known as: HGH Frag, Fragment 176-191, AOD-9604 Precursor
Growth Hormone Fragment | Fat Loss Peptide
Overview
HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.
Key benefits
- Stimulates lipolysis without growth hormone side effects
- Does not affect blood glucose or insulin sensitivity
- Does not increase IGF-1 levels
- Selectively targets fat metabolism
- No impact on bone or organ growth
Mechanism of action
Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.
Molecular data
- Type
- hGH C-terminal fragment (176-191)
- Half-life
- 15-20 minutes
Sequence
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Indications
What the research community uses this compound for, with self-reported effectiveness.
Fat Loss
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 250mcg | Twice daily (morning fasted + pre-bed) | — |
| — | 500mcg | Twice daily (morning fasted + pre-bed) | — |
| — | 250mcg | Once daily (morning, fasted) | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site irritation (redness, mild swelling)
- Headache, particularly in the first few days
- Generally well-tolerated with a favorable safety profile
Contraindications
- Pregnancy or breastfeeding
- Active cancer or history of malignancy
- WADA prohibited - athletes subject to testing must avoid
Monitoring
- Injection site reactions
- Blood glucose if combining with insulin or diabetes medications
- Body composition changes
References
Primary literature and clinical-trial data informing this entry.